The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

riverd.com

Founded Year

2002

Stage

Series A | Alive

About River Diagnostics

River Diagnostics is dedicated to the development of products for the healthcare and medical research marketplace based on the vast potential of non-invasive/non-destructive Raman spectroscopy. Today researchers in personal care, and dermatological research are using River Diagnostics' instruments to understand the metabolic processes in the skin, and other fundamental research questions.

River Diagnostics Headquarter Location

Dr. Molewaterplein 50

Ee 1979 3015 GE,

Netherlands

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

River Diagnostics Patents

River Diagnostics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2008

11/24/2015

Spectroscopy, Epidemiological study projects, Epidemiology, Infectious diseases, Cohort studies

Grant

Application Date

7/17/2008

Grant Date

11/24/2015

Title

Related Topics

Spectroscopy, Epidemiological study projects, Epidemiology, Infectious diseases, Cohort studies

Status

Grant

Latest River Diagnostics News

TechFund co-leads series "A financing round" of River Diagnostics Holding

Jul 19, 2013

Soest, November 28, 2007 TechFund announced today the closure of the Series "A financing round". The round was co-led by The Erasmus MC Biomedical Fund and TechFund. River Diagnostics develops and brings to market medical diagnostic instruments which make use of an optical technology named Raman spectroscopy. Recently, the company unveiled its technology for easy and rapid identification of bacteria at strain level, which will be a crucial tool in the fight against hospital acquired infections. It will enable infection prevention teams to monitor transmission and spreading of bacteria in hospitals and will provide early warnings in case of contaminations and potential outbreaks, caused by well known “hospital bugs”, such as MRSA. The company’s other line of business focuses on the field of dermatology. Its Skin Composition Analyzer provides detailed information about skin composition and about the penetration and effects of topically applied products. Gerwin Puppels, CEO at River Diagnostics: “We are very pleased with the closure of this financing round and with two experienced venture capital investors like the Erasmus MC Biomedical Fund and TechFund participating in the success of our company. The financing will enable River Diagnostics to launch its microorganism identification device and to further develop its other lines of business.”   “We are excited to be making this investment in River Diagnostics” says Tom Schwarz, partner at the Erasmus MC Biomedical Fund. “The company’s microorganism identification device beats the golden standard not only by identifying microorganisms real-time at strain level, but also by doing so in a rapid, high-throughput manner of 100 samples per hour after an overnight culturing step. Given the knowledge of the company’s scientific team, it is obvious that many more applications will be developed and commercialized by River Diagnostics in the coming years. I am looking forward to working closely with the management team as a new member of the company’s Supervisory Board.”   About River Diagnostics (www.riverd.com) River Diagnostics develops and brings innovative solutions for clinical diagnostics and life sciences R&D to market, based on the vast potential of Raman spectroscopy for cell and tissue characterization. River Diagnostics addresses unmet needs and untapped markets in clinical diagnostics and life sciences R&D with products and services based on Raman spectroscopy; an optical technology, which enables detailed analysis of cells and tissues. The company was founded as a spin-out of the Center for Optical Diagnostics and Therapy of the Erasmus-university Medical Center in Rotterdam, The Netherlands, with which it continues to maintain a close working relationship. About TechFund B.V. (www.tiin.net) Based in Soest, TechFund B.V. invests in ICT, Nano and Medical technology. TechFund is founded by TIIN (The Informal Investors Network BV) and Atlantic Capital B.V. and funded by a group of 35 business angels. TechFund is cofunded by TechnoPartner, a Dutch agency supported by the Department of Economic Affairs that provided seed funds. For more information, please visit www.tiin.net and www.atlanticcapital.nl About the Erasmus MC Biomedical Fund (www.erasmusmcfund.nl) The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region. The fund targets companies that are developing commercially promising products and technologies in life sciences, including pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns. For further information please contact: Willem van den Berg

You May Also Like

D
DERMING SRL

DermIng, an independent private research Institute, carries out a series of clinical trials to measure the activity and tolerance of skin care treatments and products, and also developers the very latest non-invasive diagnostic bio-engineering systems.

D
DIRAmed

DIRAmed is developing non-invasive meters that measure the levels of key constituents of the human body such as glucose, ketones, cholesterol, and therapeutic drugs. DIRAmed's meters will improve the process by which diabetics and other patients taking therapeutic drugs monitor the levels of components in blood and tissue. DIRAmed currently has investigational prototypes in clinical studies for use in improving tight glycemic control in hospital critical care continuous glucose monitoring applications. DIRAmed is also discussing other designs with selected strategic partners including the development of mobile units for personal use with or without connection to an insulin pump.

T
Truthtek

Truthtek is a spin-out company from Manchester Metropolitan University with a suite of software for the analysis of non-verbal behaviour in video streams of structured interviews. The technology combines latest psychological research in non-verbal communication with leading image recognition and analysis software. Potential applications include lie detection, where the technology is non-invasive and has shown 85% accuracy in initial trials. MTF has provided initial seed capital to the company to enable it to develop its commercial and market-entry strategy.

NeuroSky Logo
NeuroSky

NeuroSky is at the forefront of body and mind monitoring and analysis. Its technologies are at the core of innovative, wearable health and wellness consumer products. NeuroSky makes it possible for millions of consumers to capture and quantify critical health and wellness data so that they can effectively manage their mind and body health. NeuroSky delivers uniquely adaptable chips and algorithms that offer ECG multi-function cardio monitoring, and quantitive and interpretive algorithms in a powerful integrated, adaptable and extensible solution.

C
CryoPen

CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.

m
m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.